How does atezolizumab subcutaneous formulation (TECENTRIQ HYBREZA) work?

The subcutaneous formulation of atezolizumab is an immune checkpoint inhibitor indicated for the treatment of a variety of malignant tumors, including non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma and alveolar soft tissue sarcoma. Based on the original intravenous infusion version, this preparation has been modified into a subcutaneous injection form through the combined application of recombinant human hyaluronidase technology, making it more convenient for patients to receive treatment and significantly shortening the clinical operation time.

Atezolizumab is a humanized monoclonal antibody that targets programmed death-ligand 1 (PD-L1). On the surface of various tumor cells and immune cells in the tumor microenvironment, the expression of PD-L1 can inhibit the activity of T cells and help tumors escape immune surveillance. Atezolizumab binds to PD-L1 and blocks its interaction with programmed death receptor 1 (PD-1) and B7.1 receptors, thereby restoring the recognition and killing functions of T cells against tumor cells. This mechanism does not rely on traditional cytotoxicity or targeted inhibition pathways, but achieves anti-tumor effects by activating the body's immune response, becoming an important part of current immunotherapy.

The hyaluronidase component used in subcutaneous preparations comes fromEnhanze drug delivery technology, the core of which is rHuPH20, an enzyme that can temporarily degrade hyaluronic acid in subcutaneous tissue. Hyaluronic acid is a natural barrier in the subcutaneous stroma. After degradation, it can temporarily increase tissue permeability, making it easier for macromolecule drugs to diffuse and quickly enter the blood circulation. This technology allows 15 ml of medicinal solution to be injected within 7 minutes, compared with the 30 to 60 minutes required for traditional intravenous infusion, which not only saves time, but also improves the patient's treatment experience.

The clinical effectiveness and safety of subcutaneous formulations of atezolizumab have been confirmed by multiple studies. The results of the IMscin001 study showed that the subcutaneous preparation was equivalent to intravenous administration in terms of pharmacokinetic parameters, and no new safety risks were found. In the IMscin002 study, most of the patients interviewed expressed their preference for subcutaneous administration. The reasons include shortened treatment time, higher comfort and ease of coordination with the treatment plan. It is based on these research data that the U.S. Food and Drug Administration (FDA) approved the marketing of this preparation for the same therapeutic indications as the intravenous preparation.

In summary, the subcutaneous formulation of atezolizumab optimizes the route of administration while maintaining therapeutic efficacy and safety. By blockingPD-L1-related signaling pathways to activate the immune response, and using enhanced injection technology to improve drug distribution efficiency, it meets the current clinical demand for efficient and accessible tumor immunotherapy solutions.

Reference materials:https://www.drugs.com/search.php?searchterm=TECENTRIQ+HYBREZA